The use of triptans is contraindicated in patients with migraine and a history of ischemic stroke or coronary artery disease, although there’s no substantial evidence that they directly increase the risk for vascular events.
A migraine-specific adaptation of the Mindfulness-Based Cognitive Therapy (MBCT) program does not improve headache-related impairment among patients with migraine, but does result in reduced headache frequency and improved psychological functioning.
The HER-MES trial included 777 adults with episodic or chronic migraine (at least 4 migraine days/month) who were treatment-naïve, not suitable for, or had previously failed up to 3 prophylactic migraine treatments.
